Determining the mutation bias of favipiravir in influenza virus using next-generation sequencing

Journal of Virology

Volumn 93, Issue 2, 2019, Pages

  Goldhill, Daniel H ^b   Langat, Pinky ^b   Xie, Hongyao ^b   Galiano, Monica ^a   Miah, Shahjahan ^a   Kellam, Paul ^b   Zambon, Maria ^a   Lackenby, Angie ^a   Barclay, Wendy S ^b  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Favipiravir; Influenza; Mutation bias; Next generation sequencing; Primer ID

Indexed keywords

ADENINE DERIVATIVE; FAVIPIRAVIR; GUANINE DERIVATIVE; VIRUS RNA; AMIDE; PRIMER DNA; PYRAZINE DERIVATIVE;

ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; INFLUENZA VIRUS; NEXT GENERATION SEQUENCING; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RNA ANALYSIS; SANGER SEQUENCING; VIRUS MUTATION; WHOLE GENOME SEQUENCING; ANIMAL; DOG; DRUG EFFECT; GENETICS; HEK293 CELL LINE; HIGH THROUGHPUT SEQUENCING; INFLUENZA A VIRUS; MDCK CELL LINE; MUTATION; PROCEDURES; SEQUENCE ANALYSIS; STATISTICAL BIAS;

AMIDES; ANIMALS; BIAS; DNA PRIMERS; DOGS; HEK293 CELLS; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; INFLUENZA A VIRUS; MADIN DARBY CANINE KIDNEY CELLS; MUTATION; PYRAZINES; SEQUENCE ANALYSIS, RNA; WHOLE GENOME SEQUENCING;

EID: 85059497081     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01217-1     Document Type: Article

References (50)

1. World Health Organization. 2018. Influenza (seasonal) factsheet. World Health Organization, Geneva, Switzerland. www.who.int/en/news-room/fact-sheets/detail/influenza-(seasonal).
2. Ferguson NM, Cummings DAT, Fraser C, Cajka JC, Cooley PC, Burke DS. 2006. Strategies for mitigating an influenza pandemic. Nature 442:448. https://doi.org/10.1038/nature04795.
3. Fauci AS. 2006. Seasonal and pandemic influenza preparedness: science and countermeasures. J Infect DIS 194:S73–S76. https://doi.org/10.1086/507550.
4. Deyde VM, Xu X, Bright RA, Shaw M, Smith CB, Zhang Y, Shu Y, Gubareva LV, Cox NJ, Klimov AI. 2007. Surveillance of resistance to adamantanes among influenza A (H3N2) and A (H1N1) viruses isolated worldwide. J Infect Dis 196:249 –257. https://doi.org/10.1086/518936.
5. Hurt AC. 2014. The epidemiology and spread of drug-resistant human influenza viruses. Curr Opin Virol 8:22–29. https://doi.org/10.1016/j.coviro.2014.04.009.
6. Moscona A. 2009. Global transmission of oseltamivir-resistant influenza. N Engl J Med 360:953–956. https://doi.org/10.1056/NEJMp0900648.
7. Watanabe T, Kiso M, Fukuyama S, Nakajima N, Imai M, Yamada S, Murakami S, Yamayoshi S, Iwatsuki-Horimoto K, Sakoda Y, Takashita E, McBride R, Noda T, Hatta M, Imai H, Zhao D, Kishida N, Shirakura M, de Vries RP, Shichinohe S, Okamatsu M, Tamura T, Tomita Y, Fujimoto N, Goto K, Katsura H, Kawakami E, Ishikawa I, Watanabe S, Ito M, Sakai-Tagawa Y, Sugita Y, Uraki R, Yamaji R, Eisfeld AJ, Zhong G, Fan S, Ping J, Maher EA, Hanson A, Uchida Y, Saito T, Ozawa M, Neumann G, Kida H, Odagiri T, Paulson JC, Hasegawa H, Tashiro M, Kawaoka Y. 2013. Characterization of H7N9 influenza A viruses isolated from humans. Nature 501:551. https://doi.org/10.1038/nature12392.
8. Zhu H, Wang D, Kelvin DJ, Li L, Zheng Z, Yoon S-W, Wong S-S, Farooqui A, Wang J, Banner D, Chen R, Zheng R, Zhou J, Zhang Y, Hong W, Dong W, Cai Q, Roehrl MHA, Huang SSH, Kelvin AA, Yao T, Zhou B, Chen X, Leung GM, Poon LLM, Webster RG, Webby RJ, Peiris JSM, Guan Y, Shu Y. 2013. Infectivity, transmission, and pathology of human-isolated H7N9 influenza virus in ferrets and pigs. Science 341:183–186. https://doi.org/10.1126/science.1239844.
9. Imai M, Watanabe T, Kiso M, Nakajima N, Yamayoshi S, Iwatsuki-Horimoto K, Hatta M, Yamada S, Ito M, Sakai-Tagawa Y, Shirakura M, Takashita E, Fujisaki S, McBride R, Thompson AJ, Takahashi K, Maemura T, Mitake H, Chiba S, Zhong G, Fan S, Oishi K, Yasuhara A, Takada K, Nakao T, Fukuyama S, Yamashita M, Lopes TJS, Neumann G, Odagiri T, Watanabe S, Shu Y, Paulson JC, Hasegawa H, Kawaoka Y. 2017. A highly pathogenic avian H7N9 influenza virus isolated from a human is lethal in some ferrets infected via respiratory droplets. Cell Host Microbe 22: 615–626. e618. https://doi.org/10.1016/j.chom.2017.09.008.
10. Koszalka P, Tilmanis D, Hurt AC. 2017. Influenza antivirals currently in late-phase clinical trial. Influenza Other Respir Viruses 11:240–246. https://doi.org/10.1111/irv.12446.
11. De Clercq E, Li G. 2016. Approved antiviral drugs over the past 50 years. Clin Microbiol Rev 29:695–747. https://doi.org/10.1128/CMR.00102-15.
12. Furuta Y, Takahashi K, Fukuda Y, Kuno M, Kamiyama T, Kozaki K, Nomura N, Egawa H, Minami S, Watanabe Y, Narita H, Shiraki K. 2002. In vitro and in vivo activities of anti-influenza virus compound T-705. Antimicrob Agents Chemother 46:977–981. https://doi.org/10.1128/AAC.46.4.977-981.2002.
13. Sidwell RW, Barnard DL, Day CW, Smee DF, Bailey KW, Wong M-H, Morrey JD, Furuta Y. 2007. Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice. Antimicrob Agents Chemother 51:845–851. https://doi.org/10.1128/AAC.01051-06.
14. Kiso M, Takahashi K, Sakai-Tagawa Y, Shinya K, Sakabe S, Le QM, Ozawa M, Furuta Y, Kawaoka Y. 2010. T-705 (favipiravir) activity against lethal H5N1 influenza A viruses. Proc Natl Acad Sci U S A 107:882–887. https://doi.org/10.1073/pnas.0909603107.
15. Furuta Y, Takahashi K, Shiraki K, Sakamoto K, Smee DF, Barnard DL, Gowen BB, Julander JG, Morrey JD. 2009. T-705 (favipiravir) and related compounds: novel broad-spectrum inhibitors of RNA viral infections. Antiviral Res 82:95–102. https://doi.org/10.1016/j.antiviral.2009.02.198.
16. Sleeman K, Mishin VP, Deyde VM, Furuta Y, Klimov AI, Gubareva LV. 2010. In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A (H1N1) viruses. Antimicrob Agents Chemother 54:2517–2524. https://doi.org/10.1128/AAC.01739-09.
17. Furuta Y, Gowen BB, Takahashi K, Shiraki K, Smee DF, Barnard DL. 2013. Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antiviral Res 100:446–454. https://doi.org/10.1016/j.antiviral.2013.09.015.
18. Furuta Y, Komeno T, Nakamura T. 2017. Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. Proc Jpn Acad Ser B Phys Biol Sci 93:449–463. https://doi.org/10.2183/pjab.93.027.
19. Mendenhall M, Russell A, Juelich T, Messina EL, Smee DF, Freiberg AN, Holbrook MR, Furuta Y, de la Torre J-C, Nunberg JH, Gowen BB. 2011. T-705 (favipiravir) inhibition of arenavirus replication in cell culture. Antimicrob Agents Chemother 55:782–787. https://doi.org/10.1128/AAC.01219-10.
20. Mendenhall M, Russell A, Smee DF, Hall JO, Skirpstunas R, Furuta Y, Gowen BB. 2011. Effective oral favipiravir (T-705) therapy initiated after the onset of clinical disease in a model of arenavirus hemorrhagic fever. PLoS Negl Trop Dis 5:e1342. https://doi.org/10.1371/journal.pntd.0001342.
21. Oestereich L, Lüdtke A, Wurr S, Rieger T, Muñoz-Fontela C, Günther S. 2014. Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model. Antiviral Res 105:17–21. https://doi.org/10.1016/j.antiviral.2014.02.014.
22. Safronetz D, Rosenke K, Westover JB, Martellaro C, Okumura A, Furuta Y, Geisbert J, Saturday G, Komeno T, Geisbert TW, Feldmann H, Gowen BB. 2015. The broad-spectrum antiviral favipiravir protects guinea pigs from lethal Lassa virus infection post-disease onset. Sci Rep 5:14775. https://doi.org/10.1038/srep14775.
23. Oestereich L, Rieger T, Lüdtke A, Ruibal P, Wurr S, Pallasch E, Bockholt S, Krasemann S, Muñoz-Fontela C, Günther S. 2015. Efficacy of favipiravir alone and in combination with ribavirin in a lethal, immunocompetent mouse model of Lassa fever. J Infect Dis 213:934–938. https://doi.org/10.1093/infdis/jiv522.
24. Tani H, Fukuma A, Fukushi S, Taniguchi S, Yoshikawa T, Iwata-Yoshikawa N, Sato Y, Suzuki T, Nagata N, Hasegawa H. 2016. Efficacy of T-705 (favipiravir) in the treatment of infections with lethal severe fever with thrombocytopenia syndrome virus. mSphere 1:e00061-15.
25. Delang L, Abdelnabi R, Neyts J. 2018. Favipiravir as a potential countermeasure against neglected and emerging RNA viruses. Antiviral Res 153:85–94. https://doi.org/10.1016/j.antiviral.2018.03.003.
26. Furuta Y, Takahashi K, Kuno-Maekawa M, Sangawa H, Uehara S, Kozaki K, Nomura N, Egawa H, Shiraki K. 2005. Mechanism of action of T-705 against influenza virus. Antimicrob Agents Chemother 49:981–986. https://doi.org/10.1128/AAC.49.3.981-986.2005.
27. Baranovich T, Wong S-S, Armstrong J, Marjuki H, Webby RJ, Webster RG, Govorkova EA. 2013. T-705 (favipiravir) induces lethal mutagenesis in influenza A H1N1 viruses in vitro. J Virol 87:3741–3751. https://doi.org/10.1128/JVI.02346-12.
28. Arias A, Thorne L, Goodfellow I. 2014. Favipiravir elicits antiviral mutagenesis during virus replication in vivo. Elife 3:e03679. https://doi.org/10.7554/eLife.03679.
29. de Ávila AI, Gallego I, Soria ME, Gregori J, Quer J, Esteban JI, Rice CM, Domingo E, Perales C. 2016. Lethal mutagenesis of hepatitis C virus induced by favipiravir. PLoS One 11:e0164691. https://doi.org/10.1371/ journal.pone.0164691.
30. Barauskas O, Xing W, Aguayo E, Willkom M, Sapre A, Clarke M, Birkus G, Schultz BE, Sakowicz R, Kwon HJ, Feng JY. 2017. Biochemical characterization of recombinant influenza A polymerase heterotrimer complex: polymerase activity and mechanisms of action of nucleotide analogs. PLoS One 12:e0185998. https://doi.org/10.1371/journal.pone.0185998.
31. Vanderlinden E, Vrancken B, Van Houdt J, Rajwanshi VK, Gillemot S, Andrei G, Lemey P, Naesens L. 2016. Distinct effects of T-705 (favipiravir) and ribavirin on influenza virus replication and viral RNA synthesis. Antimicrob Agents Chemother 60:6679–6691. https://doi.org/10.1128/AAC.01156-16.
32. Sangawa H, Komeno T, Nishikawa H, Yoshida A, Takahashi K, Nomura N, Furuta Y. 2013. Mechanism of action of T-705 ribosyl triphosphate against influenza virus RNA polymerase. Antimicrob Agents Chemother 57:5202–5208. https://doi.org/10.1128/AAC.00649-13.
33. Jin Z, Smith LK, Rajwanshi VK, Kim B, Deval J. 2013. The ambiguous base-pairing and high substrate efficiency of T-705 (favipiravir) ribofura-nosyl 5=-triphosphate towards influenza A virus polymerase. PLoS One 8:e68347. https://doi.org/10.1371/journal.pone.0068347.
34. Jin Z, Kinkade A, Behera I, Chaudhuri S, Tucker K, Dyatkina N, Rajwanshi VK, Wang G, Jekle A, Smith DB, Beigelman L, Symons JA, Deval J. 2017. Structure-activity relationship analysis of mitochondrial toxicity caused by antiviral ribonucleoside analogs. Antiviral Res 143:151–161. https://doi.org/10.1016/j.antiviral.2017.04.005.
35. Marathe BM, Wong S-S, Vogel P, Garcia-Alcalde F, Webster RG, Webby RJ, Najera I, Govorkova EA. 2016. Combinations of oseltamivir and T-705 extend the treatment window for highly pathogenic influenza A (H5N1) virus infection in mice. Sci Rep 6:26742. https://doi.org/10.1038/srep26742.
36. Delang L, Segura Guerrero N, Tas A, Quérat G, Pastorino B, Froeyen M, Dallmeier K, Jochmans D, Herdewijn P, Bello F, Snijder EJ, de Lamballerie X, Martina B, Neyts J, van Hemert MJ, Leyssen P. 2014. Mutations in the chikungunya virus nonstructural proteins cause resistance to favipiravir (T-705), a broad-spectrum antiviral. J Antimicrob Chemother 69: 2770–2784. https://doi.org/10.1093/jac/dku209.
37. Guedj J, Piorkowski G, Jacquot F, Madelain V, Nguyen THT, Rodallec A, Gunther S, Carbonnelle C, Mentré F, Raoul H, de Lamballerie X. 2018. Antiviral efficacy of favipiravir against Ebola virus: a translational study in cynomolgus macaques. PLoS Med 15:e1002535. https://doi.org/10.1371/journal.pmed.1002535.
38. Jabara CB, Jones CD, Roach J, Anderson JA, Swanstrom R. 2011. Accurate sampling and deep sequencing of the HIV-1 protease gene using a Primer ID. Proc Natl Acad Sci U S A 108:20166 –20171. https://doi.org/10.1073/pnas.1110064108.
39. Zhou S, Jones C, Mieczkowski P, Swanstrom R. 2015. Primer ID validates template sampling depth and greatly reduces the error rate of next-generation sequencing of HIV-1 genomic RNA populations. J Virol 89: 8540–8555. https://doi.org/10.1128/JVI.00522-15.
40. Kosik I, Ince WL, Gentles LE, Oler AJ, Kosikova M, Angel M, Magadán JG, Xie H, Brooke CB, Yewdell JW. 2018. Influenza A virus hemagglutinin glycosylation compensates for antibody escape fitness costs. PLoS Pat-hog 14:e1006796. https://doi.org/10.1371/journal.ppat.1006796.
41. Wu NC, Young AP, Al-Mawsawi LQ, Olson CA, Feng J, Qi H, Chen S-H, Lu I-H, Lin C-Y, Chin RG, Luan HH, Nguyen N, Nelson SF, Li X, Wu T-T, Sun R. 2014. High-throughput profiling of influenza A virus hemagglutinin gene at single-nucleotide resolution. Sci Rep 4:4942. https://doi.org/10.1038/srep04942.
42. Doud MB, Bloom JD. 2016. Accurate measurement of the effects of all amino-acid mutations on influenza hemagglutinin. Viruses 8:155. https://doi.org/10.3390/v8060155.
43. Goldhill DH, Langat P, Xie H, Galiano M, Shahjahan M, Kellam P, Lackenby A, Barclay W. 2018. Determining the mutation bias of favipiravir in influenza virus using next-generation sequencing. bioRxiv 10.1101/ 375378.
44. Pauly MD, Procario M, Lauring AS. 2017. The mutation rates and mutational bias of influenza A virus. bioRxiv https://doi.org/10.1101/110197.
45. Visher E, Whitefield SE, McCrone JT, Fitzsimmons W, Lauring AS. 2016. The mutational robustness of influenza A virus. PLoS Pathogens 12(8): e1005856. https://doi.org/10.1371/journal.ppat.1005856.
46. Pauly MD, Lauring AS. 2015. Effective lethal mutagenesis of influenza virus by three nucleoside analogs. J Virol 89:3584–3597. https://doi.org/10.1128/JVI.03483-14.
47. Watson SJ, Welkers MR, Depledge DP, Coulter E, Breuer JM, de Jong MD, Kellam P. 2013. Viral population analysis and minority-variant detection using short read next-generation sequencing. Philos Trans R Soc Lond B Biol Sci 368:20120205. https://doi.org/10.1098/rstb.2012.0205.
48. Sheward DJ, Murrell B, Williamson C. 2012. Degenerate Primer IDs and the birthday problem. Proc Natl Acad Sci U S A 109:E1330–E1330. https://doi.org/10.1073/pnas.1203613109.
49. Long JS, Giotis ES, Moncorgé O, Frise R, Mistry B, James J, Morisson M, Iqbal M, Vignal A, Skinner MA, Barclay WS. 2016. Species difference in ANP32A underlies influenza A virus polymerase host restriction. Nature 529:101. https://doi.org/10.1038/nature16474.
50. Zhou B, Donnelly ME, Scholes DT, George KS, Hatta M, Kawaoka Y, Wentworth DE. 2009. Single-reaction genomic amplification accelerates sequencing and vaccine production for classical and Swine origin human influenza a viruses. J Virol 83:10309–10313. https://doi.org/10.1128/JVI.01109-09.